Clinical trial NCT04109820: Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
Official title: Effect of MitoQ on Platelet Function and Reactive Oxygen Species (ROS) Generation in Patients With Sickle Cell Anemia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Sickle Cell Disease
Keywords: Basal platelet activation
MitoQ
mitochondrial ROS (Reactive Oxygen Species)
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2019-09-30
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Non randomized case control study design.
Primary purpose: OTHER

Brief summary: MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease.

The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).

Detailed description: Antioxidant therapies targeted to specific enzymes or compartments may be beneficial in sickle cell anemia (SCA). MitoQ, the most extensively studied mitochondrial-targeted antioxidant, has been shown to be protective against ischemia/reperfusion injury in the heart, endothelial damage due to hypertension and ROS in animal models. MitoQ is commercially available as a dietary supplement to reduce overall oxidative stress and anti-ageing. However, MitoQ has not been tested either as a platelet antagonist or as an endothelial protectant in SCA patients. Investigators propose to conduct a small clinical trial of MitoQ in subjects with SCA to test the hypothesis that MitoQ scavenges platelet mtROS to prevent platelet activation and attenuate vascular dysfunction in SCA.

Investigators will test whether MitoQ decreases basal platelet activation in SCD patients and attenuates vascular dysfunction in subjects with SCA. Investigators will administer MitoQ orally to patients and healthy controls for 14 days. Investigators will obtain platelet count, hemolytic markers, platelet mtROS levels and activation markers, clinic BP measurements before and after MitoQ.

Adult male and female SCA subjects in steady state (n=10) and 5 healthy African-American volunteers will be recruited after obtaining informed consent.

Eligibility criteria: Inclusion Criteria:

Subjects

* African American
* Patients with sickle cell anemia
* 18 years old or older

Control

* African American healthy controls
* 18 years of age or older

Exclusion Criteria:

1. Pregnancy,
2. Known hypertension,
3. Hemodialysis and active obstructive sleep apnea requiring treatment.
4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.

Primary outcomes:
measure: Effect of MitoQ on platelet activation markers in subjects with SCA
timeFrame: Baseline to 14 days
Secondary outcomes:
measure: Effect of MitoQ on vascular dysfunction in subjects with SCA
timeFrame: Baseline to 14 days
measure: Effect of MitoQ on hemolysis in subjects with SCA
timeFrame: Baseline to 14 days
measure: Effect of MitoQ on hemolysis in subjects with SCA
timeFrame: Baseline to 14 days
measure: Effect of MitoQ on hemolysis in subjects with SCA
timeFrame: Baseline to 14 days
measure: Treatment related severe adverse events (SAE)
timeFrame: Baseline to 14 days
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Magee Women's Hospital
state: Pennsylvania
city: Pittsburgh
country: United States
facility: UPMC Montefiore
state: Pennsylvania
city: Pittsburgh
country: United States
facility: UPMC Presbyterian
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Children's Hospital of Pittsburgh
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Hillman Cancer Center
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Ramasubramanian Kalpatthi, MD
role: PRINCIPAL_INVESTIGATOR
References: